ArticleBMC microbiology2026
Prevalence of extended-spectrum β-lactamase and carbapenemase-producing Escherichia coli from patients, cattle, and environmental sources in northwest Amhara, Ethiopia: a one health approach.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEscherichia coli (E. coli) is a Gram-negative, ubiquitous bacterium found in humans, animals, and the environment. Certain strains, notably extended-spectrum β-lactamase-producing E. coli (ESBL-PEC) and carbapenemase-producing E. coli (CPEC), cause life-threatening intestinal and extraintestinal infections. While some studies exist in patients, data on the prevalence of ESBL-PEC and CPEC among human patients, cattle, and the environment, using a One Health approach, are limited. We aimed to determine the prevalence of ESBL-PEC and CPEC among patients, cattle, and the environment in northwest Amhara, Ethiopia, using a One Health approach.
methodsA cross-sectional study was conducted from January to August 2025 among 972 study participants, including human patients (508), animals (158), and environmental samples (306). Consecutive sampling was used to select patients and animals. Purposive sampling was used to select environmental samples. Urine or blood from patients, recto-anal mucosal swab from animals, swab, and wastewater from the environment were collected and processed for E. coli isolation using standard microbiological methods. ESBL-PEC and CPEC were identified using a combination disk diffusion test and a modified carbapenem inactivation method, respectively, in accordance with the Clinical Laboratory Standard Institute guidelines. Associations were assessed using Chi-square in SPSS, and antimicrobial resistance (AMR) profiles of E. coli isolates using a heatmap in R software.
resultsThe prevalence of ESBL-PEC among E. coli isolated from patients was 52.4% (33/63, 95% CI: 40.3-64.2), while 33.3% (24/72, 95% CI: 23.5-44.8) among environmental isolates and 6.6% (10/151, 95% CI: 3.6-11.8) among cattle isolates. The prevalence of CPEC among patient isolates was 9.5% (6/63, 95% CI: 4.4-19.3) and 2.8% (2/72, 95% CI: 0.8-9.6) in environmental isolates, while no CPEC was detected among cattle isolates. All ESBL-PEC and CPEC isolates were multidrug resistant (MDR). Among non-β-lactam antibiotics tested, ESBL-PEC and/or CPEC isolates showed the highest co-resistance to ciprofloxacin (81.3%), followed by gentamicin (56%), while the lowest was for amikacin (17.3%). Overall, 90.5% (57/63) of E. coli from patients, and 81.9% (59/72) from environmental sources, and 29.1% (44/151) from cattle were MDR.
conclusionsThe prevalence of ESBL-PEC and CPEC was high in patients and the hospital environment, whereas ESBL-PEC was low in cattle. No CPEC was detected in cattle. Widespread MDR E. coli presence in patients, the environment, and cattle underscores the need for reinforced infection prevention and control measures in hospitals and AMR surveillance based on a One Health approach.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.